Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
暂无分享，去创建一个
H. Dombret | M. Béné | T. Cluzeau | G. Guillerm | C. Récher | K. Laribi | I. Vaida | E. Jourdan | E. Raffoux | Stéphanie Haiat | S. Bertoli | A. Pigneux | C. Pautas | A. Banos | Juliette Lambert | P. Dumas | P. Turlure | M. Uzunov | C. Bonmati | M. Hospital | M. Chrétien | C. Orvain | M. Wémeau | M. Heiblig | A. Santagostino | P. Peterlin | R. Guiéze | A. Marçais | E. Bérard | E. Tavernier | C. Himberlin | T. Marchand | Florence Pasquier | S. Chantepie | Y. Desbrosses | M. Carré | Eve Gehlkopf | A. Villate | H. Debarri | S. Chebrek | J. Frayfer | Ariane C. Mineur | R. Guièze | J. Lambert | Ariane C Mineur